

One drug fits all

Cancer drugs are usually approved for specific tumor types—breast, prostate, etc. But tissue-agnostic drugs can treat any tumor as long it has a specific molecular alteration. Here are some of those drugs under development.

| DRUG | COMPANY | TARGETED MOLECULAR ALTERATION | STATUS |
|--------------------------|---------------------|--|-----------------|
| Pembrolizumab (Keytruda) | Merck | Mismatch repair deficiency | Approved 23 May |
| Larotrectenib (Loxo-101) | Loxo Oncology | TRK fusions | Phase II |
| Entrectenib | Ignitya | TRK, ALK, and ROS1 fusions | Phase II |
| Loxo-195 | Loxo Oncology | Loxo-101 resistant TRK fusions | Phase I |
| Loxo-292* | Loxo Oncology | RET fusions and activating point mutations | Phase I |
| RXDX-105* | Ignitya | RET alterations | Phase I |
| TPX-0005 | TP Therapeutics | TRK, ALK, and ROS1 fusions | Phase I/II |
| BLU-667* | Blueprint Medicines | RET alterations | Phase I/II |

*Agnostic indication contingent on early trial data